ArticleScientific reports2025
Efficacy of Lacticaseibacillus rhamnosus probiotic strains in treating chromate induced dermatitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Draft genome sequence of a chromium-resistant Bacillus altitudinis AK25 strain isolated from contaminated aquatic environment.BMC genomic data · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromate induced dermatitis is a significant occupational health concern. Chromate (Cr) resistant Lacticaseibacillus rhamnosus strains were isolated from commercial probiotic sachets PREPRO and HiFLORA. Among 13 Cr-resistant bacterial isolates, six were selected based on high chromate resistance at 500 ug/ml. Selected isolates were subjected to biochemical and molecular characterization and in vivo analyses. DPC assay was conducted under controlled conditions in order to determine the reduction potential of the isolated bacteria. The selected isolates were identified as L. rhamnosus-L1 (PP493917), L. rhamnosus-L2 (PP493918), L. rhamnosus-L3 (PP493921) L. rhamnosus-L4 (PP493920) L. rhamnosus-L8 (PP493922) and L. rhamnosus-L12 (PP493923). Lacticaseibacillus rhamnosus L1showed highest resistance against Cr (VI) with reduction potential 56%. In vivo experiments were performed to assess the healing effects of isolated bacterial strains on mice skin, with Hematoxylin and Eosin (H&E) staining used to identify severe dermatitis in skin tissue and evaluate therapeutic effects of probiotic strains. The structural determination of flavin reductase protein of L. rhamnosus was carried out using bioinformatics tools. These tools predicted the structural-based functional homology of flavin reductase protein in bacterial Cr (VI)-detoxification system. Lacticaseibacillus rhamnosus can be effectively used against chromate-induced dermatitis due to its high chromate resistance and reduction potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.